Carregant...

A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer

Mutational testing has moved to the forefront as an integral component in the management of patients with non-small cell lung cancer (NSCLC). Currently there are three targeted therapies (erlotinib, afatinib, and crizotinib) approved by the Food and Drug Administration (FDA) to treat patients with s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lammers, Philip E., Lovly, Christine M., Horn, Leora
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4151469/
https://ncbi.nlm.nih.gov/pubmed/24453288
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!